Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
101 stopped studies mapped to Malignant Peritoneal and Retroperitoneal Neoplasm and descendants · 91% state a reason
Over the 101 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01952249 | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian(SIERRA) | Phase 1 | terminated | Sep 27, 2013 | OncoMed Pharmaceuticals, Inc. | Phase 2 portion not initiated, no longer pursuing ovarian cancer indication | Other (stated, no rule matched) |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Phase 1 / Phase 2 | terminated | Feb 17, 2012 | South Plains Oncology Consortium | drug combination not providing any efficacy. Will use this data in opening new trial | Efficacy / futility |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive…(HIPEC) | Phase 2 | withdrawn | Jul 2, 2015 | Krankenhaus Barmherzige Schwestern Linz | actually limited personnel ressources | Other (stated, no rule matched) |
| NCT01086696 | A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors… | Early Phase 1 | terminated | Mar 15, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | Phase 1 | terminated | Jan 25, 2016 | Dana-Farber Cancer Institute | Company decided not to move forward with further accrual. | Enrollment / accrual |
| NCT02720484 | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | Phase 2 | terminated | Mar 28, 2016 | Northwestern University | Study did not meet first stage requirements of interim analysis | Efficacy / futility |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial… | Phase 2 | withdrawn | Oct 28, 2016 | M.D. Anderson Cancer Center | PI's request | Other (stated, no rule matched) |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With… | Phase 1 / Phase 2 | terminated | Mar 9, 2010 | University Health Network, Toronto | Slow accrual | Enrollment / accrual |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or… | Phase 2 | terminated | May 8, 2006 | Dana-Farber Cancer Institute | Early closure based on audit by study investigators after 3 patients died on study. | Other (stated, no rule matched) |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive… | Phase 1 / Phase 2 | terminated | May 29, 2009 | Dana-Farber Cancer Institute | Terminated due to unacceptable toxicity | Safety / toxicity |
| NCT00899093 | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian… | — | terminated | May 12, 2009 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00003453 | Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow enrollment | Enrollment / accrual |
| NCT02833506 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian… | Phase 1 | withdrawn | Jul 14, 2016 | Roswell Park Cancer Institute | production of adjuvant to be used with vaccine was discontinued by sponsor | Other (stated, no rule matched) |
| NCT00408070 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary… | Phase 2 | terminated | Dec 6, 2006 | UConn Health | Did not meet accrual goals. | Enrollment / accrual |
| NCT00331422 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian… | Phase 2 | terminated | May 31, 2006 | Masonic Cancer Center, University of Minnesota | Study was terminated due to lack of available funding. | Funding |
| NCT00652899 | Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian… | Phase 2 | terminated | Apr 4, 2008 | Masonic Cancer Center, University of Minnesota | Withdrawn due to toxicity | Safety / toxicity |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial… | Phase 1 / Phase 2 | terminated | May 18, 2009 | Masonic Cancer Center, University of Minnesota | lack of funding | Funding |
| NCT00287859 | Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary… | Phase 1 | terminated | Feb 7, 2006 | Masonic Cancer Center, University of Minnesota | Withdrawn due to low accrual | Enrollment / accrual |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and… | Phase 1 | withdrawn | Jul 13, 2016 | Vanderbilt-Ingram Cancer Center | Loss of funding support | Funding |
| NCT00354601 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian… | Phase 2 | terminated | Jul 20, 2006 | Wake Forest University Health Sciences | funding withdrawn | Funding |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients… | Phase 2 | terminated | Aug 25, 2003 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00551265 | Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage… | N/A | withdrawn | Oct 30, 2007 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | Phase 2 | terminated | Oct 30, 2013 | Dana-Farber Cancer Institute | due to slow accrual | Enrollment / accrual |
| NCT01138137 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | Phase 1 | withdrawn | Jun 7, 2010 | OHSU Knight Cancer Institute | No funding was available for the cost of the IV N-acetylcysteine (NAC). | Funding |
| NCT01137071 | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or… | Phase 2 | terminated | Jun 4, 2010 | Recepta Biopharma | Total number of pts expected to be enrolled would not be met. | Enrollment / accrual |
| NCT01493505 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and… | Phase 3 | terminated | Dec 16, 2011 | Amgen | Amgen Administrative Decision - termination of LTFU | Other (stated, no rule matched) |
| NCT00901836 | Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma(SA03) | N/A | terminated | May 14, 2009 | University of Florida | Study closed due to feasability | Other (stated, no rule matched) |
| NCT00637390 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal… | Phase 1 | terminated | Mar 18, 2008 | University of Michigan Rogel Cancer Center | Genzyme will no longer supply the study drug for this trial as it does not believe the study will… | Drug supply |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced… | Phase 1 | withdrawn | Dec 11, 2015 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT00634894 | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary… | Phase 2 | withdrawn | Mar 13, 2008 | M.D. Anderson Cancer Center | Study halted with no registration, the drug company sponsor withdrew support. | Sponsor / business decision |
| NCT02470559 | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients… | Phase 1 | withdrawn | Jun 12, 2015 | Barbara Ann Karmanos Cancer Institute | Study did not accrue any participants, the PI has left the institution. | Enrollment / accrual |
| NCT00053235 | Research Study in Patients With Advanced Ovarian Epithelial Cancer | — | withdrawn | Jan 28, 2003 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01832974 | Possible New Therapy for Advanced Cancer | Phase 1 | terminated | Apr 16, 2013 | INSYS Therapeutics Inc | Business decision by the sponsor during Phase 1. | Sponsor / business decision |
| NCT00469469 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | Phase 2 | withdrawn | May 4, 2007 | Dartmouth-Hitchcock Medical Center | unable to enroll subjects into the study | Enrollment / accrual |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With… | Phase 3 | withdrawn | Dec 15, 2011 | Gynecologic Oncology Group | Withdrawn | Other (stated, no rule matched) |
| NCT00536523 | Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With… | — | terminated | Sep 28, 2007 | University of Minnesota | Funding unavailable | Funding |
| NCT00778817 | IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That… | Phase 2 | terminated | Oct 23, 2008 | National Cancer Institute (NCI) | The trial was permanently halted due to futility concerns. | Efficacy / futility |
| NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian… | Phase 1 | terminated | Sep 16, 2010 | New Mexico Cancer Research Alliance | Terminated due to inadequate rate of accrual. | Enrollment / accrual |
| NCT01821859 | Abraxane/Bevacizumab | Phase 2 | terminated | Apr 1, 2013 | OHSU Knight Cancer Institute | Terminated due to low enrollment | Enrollment / accrual |
| NCT00748527 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced… | Phase 2 | terminated | Sep 8, 2008 | Cancer Research UK | The study was "withdrawn" due to certain adverse events \[hypersensitivity\]. | Safety / toxicity |
| NCT00369954 | Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian… | Phase 2 | withdrawn | Aug 30, 2006 | Gynecologic Oncology Group | Trial was never activated | Other (stated, no rule matched) |
| NCT00002921 | S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer… | Phase 2 | terminated | Jul 30, 2004 | SWOG Cancer Research Network | Permanently Closed Due to Lack of Accrual | Enrollment / accrual |
| NCT00669422 | ChemoFx® PRO - A Post-Market Data Collection Study | — | terminated | Apr 30, 2008 | Precision Therapeutics | not stated | Not stated |
| NCT01661868 | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer | Phase 2 | withdrawn | Aug 10, 2012 | Dana-Farber Cancer Institute | Drug not available. | Other (stated, no rule matched) |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial,… | Phase 1 / Phase 2 | terminated | Jun 11, 2004 | M.D. Anderson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT00897806 | Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly… | — | terminated | May 12, 2009 | M.D. Anderson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary… | Phase 2 | terminated | Apr 4, 2008 | Vanderbilt-Ingram Cancer Center | Abbott (drug manufacturer) discontinued manufacture of ABT-627 | Drug supply |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | Phase 2 | terminated | Jul 23, 2007 | M.D. Anderson Cancer Center | Terminated due to slow patient accrual. | Enrollment / accrual |
| NCT01096381 | Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid… | — | terminated | Mar 31, 2010 | Vanderbilt-Ingram Cancer Center | funding withdrawn due to fellow's departure from VICC | Funding |
| NCT00753480 | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial… | Phase 1 | suspended | Sep 16, 2008 | Genentech, Inc. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 9, 2020source: clinicaltrials